Skip to main content Accessibility help

Attributable Costs and Length of Stay of an Extended-Spectrum Beta-Lactamase-Producing Klebsiella pneumoniae Outbreak in a Neonatal Intensive Care Unit

  • Patricia W. Stone (a1), Archana Gupta (a2), Maureen Loughrey (a3), Phyllis Della-Latta (a4), Jeannie Cimiotti (a1), Elaine Larson (a1) (a5), David Rubenstein (a2) and Lisa Saiman (a2) (a5)...



To determine the costs of the interventions aimed at controlling the 4-month outbreak and to determine the attributable length of stay (LOS) associated with infection and colonization with extended-spectrum beta-lactamase-producing Klebsiella pneumoniae.


A retrospective cost analysis was conducted from the hospital perspective. A micro-costing approach was employed. The LOS of four groups of hospitalized patients were compared with each other. National Perinatal Information Center criteria were used to stratify infants for severity of risk. The LOS of each group was compared with that of a national sample of similarly stratified infants.


A level III-IV, 45-bed neonatal intensive care unit.


Infant groups were infected (n = 8), colonized (n = 14), concurrent cohort (n = 54), and prior cohort (n = 486).


The cost of the outbreak totaled $341,751. The largest proportion of costs was related to healthcare worker time providing direct patient care (2,489 hours at a cost of $146,331). Infected and colonized neonates had longer LOS than either the concurrent cohort or the prior cohort (P < .001). Compared with the national sample, infected infants had a 48.5-day longer mean LOS (95% confidence interval [CI95], 1.7 to 95.2), whereas the prior cohort's mean LOS was 6 days shorter (CI95, -9.4 to -2.9).


This study increases the understanding of the burden of these multidrug-resistant organisms. Further research is needed to estimate the societal costs of these infections and the cost-effectiveness of preventive interventions.


Corresponding author

617 West 168th Street, New York, NY 10032


Hide All
1.Jarvis, WR. Selected aspects of the socioeconomic impact of nosocomial infections: morbidity, mortality, cost, and prevention. Infect Control Hosp Epidemiol 1996;17:552557.
2.Centers for Disease Control and Prevention. Monitoring hospital-acquired infections to promote patient safety: United States, 1990-1999. MMWR 2000;49:149153.
3.Flaherty, JP, Weinstein, RA. Nosocomial infection caused by antibiotic-resistant organisms in the intensive-care unit. Infect Control Hosp Epidemiol 1996;17:236248.
4.Pillay, T, Pillay, DG, Adhikari, M, Sturm, AW. Piperacillin/tazobactam in the treatment of Klebsiella pneumoniae infections in neonates. Am J Perinatal 1998;15:4751.
5.Gonzalez-Vertiz, A, Alcantar-Curiel, D, Cuauhtli, M, et al.Multiresistant extended-spectrum beta-lactamase-producing Klebsiella pneumoniae causing an outbreak of nosocomial bloodstream infection. Infect Control Hosp Epidemiol 2001;22:723725.
6.Hart, CA. Klebsiella and neonates. J Hosp Infect 1993;23:8386.
7.Lin, H. Antibiotic resistance in bacteria: a current and future problem. Adv Exp Med Biol 1999;455:387396.
8.Otman, J, Cavassin, ED, Perugini, ME, Vidotto, MC. An outbreak of extended-spectrum beta-lactamase-producing Klebsiella species in a neonatal intensive care unit in Brazil. Infect Control Hosp Epidemiol 2002;23:89.
9.Johnson, AP, Weinbren, MJ, Ayling-Smith, B, Du Bois, SK, Amyes, SG, George, RC. Outbreak of infection in two UK hospitals caused by a strain of Klebsiella pneumoniae resistant to cefotaxime and ceftazidime. J Hosp Infect 1992;20:97103.
10.Pena, C, Pujol, M, Ardanuy, C, et al.An outbreak of hospital-acquired Klebsiella pneumoniae bacteremia, including strains producing extended-spectrum beta-lactamase. J Hosp Infect 2001;47:5359.
11.Rebuck, JA, Olsen, KM, Fey, PD, Langnas, AN, Rupp, ME. Characterization of an outbreak due to extended-spectrum beta-lactamase-producing Klebsiella pneumoniae in a pediatric intensive care unit transplant population. Clin Infect Dis 2000;31:13681372.
12.Royle, J, Halasz, S, Eagles, G, et al.Outbreak of extended spectrum beta lactamase producing Klebsiella pneumoniae in a neonatal unit. Arch Dis Child Fetal Neonatal Ed 1999;80:F64F68.
13.Gross, R, Morgan, AS, Kinky, DE, Weiner, M, Gibson, GA, Fishman, NO. Impact of a hospital-based antimicrobial management program on clinical and economic outcomes. Clin Infect Dis 2001;33:289295.
14.Goldmann, DA, Huskins, WC. Control of nosocomial antimicrobial-resistant bacteria: a strategic priority for hospitals worldwide. Clin Infect Dis 1997;24:S139S145.
15.Nathisuwan, S, Burgess, DS, Lewis, JS. Extended-spectrum beta-lactamases: epidemiology, detection, and treatment. Pharmacotherapy 2001;21:920928.
16.Saiman, L, Lerner, A, Saal, L, et al.Banning artificial nails from health care settings. Am J Infect Control 2002;30:252254.
17.Stone, PW, Larson, EL, Kawar, L. A systematic audit of economic evidence linking nosocomial infections and infection control interventions: 1990-2000. Am J Infect Control 2002;30:145152.
18.U.S. Department of Labor. Consumer Price Indices. Washington, DC: U.S. Department of Labor; 2001. Available at Accessed January 5, 2002.
19.Gupta, A, Gabriel, P, Todd, B, et al.An outbreak of extended spectrum beta-lactamase producing Klebsiella pneumoniae in a neonatal intensive care unit. Presented at the 12th Annual Scientific Meeting of the Society for Healthcare Epidemiology of America; April 6-9, 2002; Salt Lake City, UT.
20.Gold, MR, Siegel, JE, Russell, LB, Weinstein, MC. Cost-Effectiveness in Health and Medicine. New York: Oxford University Press; 1996.
21.Centers for Disease Control and Prevention. Assessing the effectiveness of disease and injury prevention programs: costs and consequences. MMWR Recomm Rep 1995;44(RR10):110.
22.Agreement Between The New York State Nurses Association & New York Presbyterian Hospital: January 1, 1999 - December 31, 2001. Latham, NY: New York Nurses Association; 2000.
23.U.S. Department of Labor, Bureau of Labor Statistics. Occupational Employment Statistics. Washington, DC: U.S. Department of Labor, Bureau of Labor Statistics; 2000. Available at Accessed January 5, 2002.
24.Cardinale, V, Chi, JC, eds. Drug Topics Red Book. Montvale, NJ: Medical Economics; 1995.
25.Schwartz, RM, Gagnon, DE, Muri, JH, Zhao, QR, Kellogg, R. Administrative data for quality improvement. Pediatrics 1999;103(1 suppl E):291301.
26.Paidos Health Management Services, Inc. What Paidos Does. Deerfield, IL: Paidos Health Management Services; 2000. Available at Accessed January 8, 2002.
27.Wenzel, RP. The Lowbury lecture: the economics of nosocomial infections. J Hosp Infect 1995;31:7987.
28.Astagneau, P, Fleury, L, Leroy, S, et al.Cost of antimicrobial treatment for nosocomial infections based on a French prevalence survey. J Hosp Infect 1999;42:303312.
29.Schulgen, G, Kropec, A, Kappstein, I, Daschner, F, Schumacher, M. Estimation of extra hospital stay attributable to nosocomial infections: heterogeneity and timing of events. J Clin Epidemiol 2000;53:409417.
30.Dominguez, TE, Chalom, R, Costatino, AT Jr. The impact of adverse patient occurrences on hospital costs in the pediatric intensive care unit. Crit Care Med 2001;29:169174.
31.Coello, R, Glenister, H, Fereres, J, et al.The cost of infection in surgical patients: a case-control study. J Hosp Infect 1993;25:239250.
32.Spearing, NM, Jensen, A, McCall, BJ, Neill, AS, McCormack, JG. Direct costs associated with a nosocomial outbreak of Salmonella infection: an ounce of prevention is worth a pound of cure. Am J Infect Control 2000;28:5457.
33.Saint, S, Veenstra, DL, Lipsky, BA, The clinical and economic consequences of nosocomial central venous catheter-related infection: are antimicrobial catheters useful? Infect Control Hosp Epidemiol 2000;21:375380.
34.Digiovine, B, Chenoweth, C, Watts, C, Higgins, M. The attributable mortality and costs of primary nosocomial bloodstream infections in the intensive care unit. Am J Respir Crit Care Med 1999;160:976981.
35.Pittet, D, Tarara, D, Wenzel, RP. Nosocomial bloodstream infection in critically ill patients: excess length of stay, extra costs, and attributable mortality. JAMA 1994;271:15981601.
36.Faoagali, JL, Darcy, D. Chickenpox outbreak among the staff of a large, urban adult hospital: costs of monitoring and control. Am J Infect Control 1995;23:247250.
37.The Brooklyn Antibiotic Resistance Task Force. The cost of antibiotic resistance: effect of resistance among Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, and Pseudomonas aeruginosa on length of hospital stay. Infect Control Hosp Epidemiol 2002;23:106108.
38.Stone, PW, Chapman, RH, Sandberg, EA, Liljas, B, Neumann, PJ. Measuring costs in cost-utility analyses: variations in the literature. Int J Technol Assess Health Care 2000;16:111124.
39.Reilly, J, Twaddle, S, Mcintosh, J, Kean, L. An economic analysis of surgical wound infection. J Hosp Infect 2001;49:245249.

Attributable Costs and Length of Stay of an Extended-Spectrum Beta-Lactamase-Producing Klebsiella pneumoniae Outbreak in a Neonatal Intensive Care Unit

  • Patricia W. Stone (a1), Archana Gupta (a2), Maureen Loughrey (a3), Phyllis Della-Latta (a4), Jeannie Cimiotti (a1), Elaine Larson (a1) (a5), David Rubenstein (a2) and Lisa Saiman (a2) (a5)...


Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed